Prediction of Successful Amorphous Solid Dispersion Pairs through Liquid State Nuclear Magnetic Resonance
Molecular Pharmaceutics · 02.12.2024 · 21 (12) · 6153-6165
DOI: 10.1021/acs.molpharmaceut.4c00359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.11.2024. Verfasst von Ana L Coutinho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States. Hauptthemen laut MEDLINE: Nitriles, Magnetic Resonance Spectroscopy, Pyrimidines, Pyridazines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, FDA HHS, U.S. Food and Drug Administration.
Abstract (Originalsprache)
Amorphous solid dispersions (ASDs) function in part via a "parachute effect", i.e., polymer-enabled prolonged drug supersaturation, presumably through drug-polymer interactions in the liquid state. We aim to expand the utility of liquid state nuclear magnetic resonance (1HNMR) to streamline polymer selection for ASDs. Our hypothesis is that strong molecular interactions between polymer and drug in 1HNMR anticipate reduced precipitation kinetics in supersaturation studies. For three drug-polymer pairs (i.e., etravirine with each HPMC, HPMCAS-M, and PVP-VA), 1HNMR findings were compared to more common supersaturation studies. Drug-polymer interactions were assessed by saturation transfer difference NMR (STD-NMR) and T1 relaxation time. 2D-1H NOESY experiments were also performed. Supersaturation studies involved precipitation inhibition using the solvent-shift methodology. The results from STD-NMR and T1 relaxation time indicate etravirine bound preferably to HPMCAS-M > HPMC ≫ PVP-VA. STD-NMR and T1 relaxation time yielded insight into which fragments of etravirine structure bind with HPMCAS-M and HPMC. The strong interactions from STD-NMR and T1 relaxation time changes indicated that HPMCAS-M and HPMC, but not PVP-VA, are suitable polymers to maintain etravirine supersaturation and inhibit drug precipitation. 2D-1H NOESY results corroborate the findings of STD-NMR and T1 relaxation time, showing that etravirine interacts preferably to HPMCAS-M than to PVP-VA. Supersaturation studies using solvent-shift technique corroborated our hypothesis as predissolved HPMCAS-M and HPMC, but to a less extent PVP-VA, markedly promoted etravirine supersaturation and inhibited drug precipitation. Supersaturation studies agreed with STD-NMR and T1 relaxation time predictions, as HPMC and HPMCAS-M maintained etravirine in solution for longer time than PVP-VA. The results show promise of 1HNMR to streamline polymer selection in a nondestructive and resource sparing fashion for subsequent ASD development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States.
ORCID-Profile: James E Polli
Förderung
- NIGMS NIH HHS
- FDA HHS
- U.S. Food and Drug Administration
- National Institute of General Medical Sciences
- Marilyn Shangraw
Zitieren
APA
Coutinho, A. L., Hom, K., & Polli, J. E. (2024). Prediction of Successful Amorphous Solid Dispersion Pairs through Liquid State Nuclear Magnetic Resonance. Molecular Pharmaceutics, 21(12), 6153-6165. https://doi.org/10.1021/acs.molpharmaceut.4c00359
Vancouver
Coutinho AL, Hom K, Polli JE. Prediction of Successful Amorphous Solid Dispersion Pairs through Liquid State Nuclear Magnetic Resonance. Molecular Pharmaceutics. 2024;21(12):6153-6165. doi:10.1021/acs.molpharmaceut.4c00359
BibTeX
@article{Coutinho2024,
author = {Coutinho, Ana L and Hom, Kellie and Polli, James E},
title = {Prediction of Successful Amorphous Solid Dispersion Pairs through Liquid State Nuclear Magnetic Resonance},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {12},
pages = {6153--6165},
doi = {10.1021/acs.molpharmaceut.4c00359}
}
EUVIMED